Actively Recruiting

MALE
NCT06473259

Evaluation of Clinical Outcomes of Chemotherapy or Androgen-receptor Targeting Agent (Alone or Combined) or Radiotherapy on Primary Tumor in Addition to Androgen Deprivation Therapy in HOrmone-Sensitive Metastatic Prostate Cancer Patients

Led by Santa Chiara Hospital · Updated on 2024-06-25

3000

Participants Needed

3

Research Sites

624 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The aim of this observational study is to evaluate the clinical outcomes of treatment with docetaxel, ARTA (alone or in combination) or with radiotherapy on the primary tumor for mCSPC, in an unselected population, in clinical practice

CONDITIONS

Official Title

Evaluation of Clinical Outcomes of Chemotherapy or Androgen-receptor Targeting Agent (Alone or Combined) or Radiotherapy on Primary Tumor in Addition to Androgen Deprivation Therapy in HOrmone-Sensitive Metastatic Prostate Cancer Patients

Who Can Participate

MALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Histologically confirmed diagnosis of adenocarcinoma of the prostate with metastatic disease, not previously treated except hormone therapy started no more than 4 to 6 months before docetaxel
  • Treatment with docetaxel, androgen receptor pathway inhibitors alone or in combination, or radiotherapy on the primary tumor combined with androgen deprivation therapy started between January 2015 and December 2027
  • Availability of inpatient and/or outpatient medical records for clinical data collection
Not Eligible

You will not qualify if you...

  • Histological diagnosis other than adenocarcinoma
  • Previous multiple lines of androgen deprivation therapy for metastatic hormone-sensitive prostate cancer
  • Previous treatment with docetaxel or androgen receptor targeting agents for metastatic castration-resistant prostate cancer

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 3 locations

1

Azienda Ospedaliera San Luigi

Orbassano, Torino, Italy, 10043

Actively Recruiting

2

Istituto Oncologico Veneto

Padova, Italy, 35128

Actively Recruiting

3

Santa Chiara Hospital

Trento, Italy, 38122

Actively Recruiting

Loading map...

Research Team

O

Orazio Caffo, MD

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

4

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Evaluation of Clinical Outcomes of Chemotherapy or Androgen-receptor Targeting Agent (Alone or Combined) or Radiotherapy on Primary Tumor in Addition to Androgen Deprivation Therapy in HOrmone-Sensitive Metastatic Prostate Cancer Patients | DecenTrialz